A retrospective cohort analysis shows that pediatric patients with noninfectious uveitis face lower recurrence rates when ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow ...

Antibiotics are commonly prescribed to young children to combat conditions such as ear infections and pneumonia. But the ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic ...

Researchers have highlighted the connection between early repeated antibiotic use and how it impacts the digestive microbiome ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules - corrected: reference to date of product launch in Europe removed; link to "Important Safety Information" updated Company aims ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Coherus BioSciences, Inc.’s CHRS share price has dipped by 5.19%, which has investors questioning if this is right time to ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market ...